COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge리툭시 맙 후 B 세포 고갈 된 환자의 Covid-19 : 진단 및 치료 문제Review Published on 2021-11-032022-08-31 Journal: Frontiers in Immunology [Category] MERS, SARS, 바이오마커, 진단, [키워드] adaptive Adaptive immunity Affect anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal antibodies Antiviral treatment association Autoimmune disorders B cell B cell immunodeficiency B cell-depletion challenge Course COVID-19 deficiencies diagnostics disease Effect exposure to function hematologic hyperimmune convalescent plasma immune Immunity Immunotherapy Impact Interpretation involved long term malignancies Measures Musculoskeletal Protective rituximab SARS-CoV-2 SARS-COV-2 infection serological significantly Therapeutic approach therapeutic strategy vaccine responses variety [DOI] 10.3389/fimmu.2021.763412 PMC 바로가기 [Article Type] Review
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?][SARS-CoV-2 반응성 T 세포는 체액성 반응이 손상된 항-CD20 치료를 받는 환자에서 감지 가능하고 잠재적으로 보호 가능한가요?]Article Published on 2021-11-012022-09-11 Journal: Zeitschrift Fur Rheumatologie [Category] SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD20 treatment antibody formation B cell cellular Cellular and humoral immunity Cellular immune response changed chronic inflammatory disease chronic inflammatory diseases Contact coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 depleting detectable effective English fatality framework Gut humoral Humoral immunity immune system Immunosuppression Infection Inflammatory diseases less life Masks monoclonal antibody obligatory organ Organ transplant pandemic pathogen Patient patients treated Probability Protective reactive recent Rheumatic diseases risk rituximab RTX SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 vaccination. severe acute respiratory syndrome Coronavirus severity Spread T cell vaccination Vaccinations virus Welt [DOI] 10.1007/s00393-021-01083-3 PMC 바로가기 [Article Type] Article
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies질병 변형 요법으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 mRNA 백신 접종의 효과Observational Study Published on 2021-09-222022-09-12 Journal: EBioMedicine [Category] MERS, 임상, 진단, [키워드] Affect analyzed anti-CD20 therapy anti-CD20 treatment antibody antigens assessments Blood blood collection BNT162b2 BNT162b2 vaccine Cellular immune response contribute coronavirus correlated decrease detectable disease Effect electrochemiluminescence immunoassay elicit evaluate the effect finding Follow-up funding humoral immune response Immunomodulatory therapies interval Italian Linear regression Moderna mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based SARS-CoV-2 vaccines multicenter cohort study Multiple multiple sclerosis multivariable multivariable analysis Patient patients treated reduced SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 vaccine sclerosis second dose serological assessment significantly the vaccine therapy untreated patients vaccination Vaccine vaccine dose Vaccines [DOI] 10.1016/j.ebiom.2021.103581 PMC 바로가기 [Article Type] Observational Study
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer암에 대한 적극적인 치료를 받는 환자의 SARS-CoV-2 백신 접종 효능 개선에 대한 현재 전망Review Published on 2021-09-012022-09-12 Journal: European journal of cancer (Oxford, England : 1990 [Category] MERS, 진단, [키워드] accelerated anti-CD20 treatment appear ARNm Cancer coronavirus disease Coverage COVID-19 current death dependent on dose Double-dose effective Efficacy evaluated global pandemic haematological malignancy heterologous prime-boost Heterologous prime-boost vaccination higher risk humoral immune response immune stimulation Immunocompromised patient immunogenicity Impaired less mRNA vaccine Patient Patients with cancer Perspective repeated reported SARS-CoV-2 SARS-CoV-2 vaccination shown solid cancer the SARS-CoV-2 therapeutic third dose Treatment trials Tumours vaccination Vaccine [DOI] 10.1016/j.ejca.2021.06.008 PMC 바로가기 [Article Type] Review
Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis다발성 경화증 환자에서 리툭시맙 투여 후 SARS-CoV-2 재활성화Case Reports Published on 2021-07-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] SARS, 바이오마커, 진단, 치료기술, [키워드] Admission alveolar anti-CD20 anti-CD20 treatment Antibody testing conditions COVID-19 highly active Hypogammaglobulinemia infected with SARS-CoV-2 infusion IVIG Multiple multiple sclerosis Nasopharyngeal swab nasopharyngeal swabs other conditions Reactivation receiving reduce Reinfection reported required respiratory respiratory symptom respiratory symptoms risk rituximab SARS-CoV-2 SARS-COV-2 infection sclerosis Treatment [DOI] 10.1016/j.msard.2021.102922 PMC 바로가기 [Article Type] Case Reports
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published CasesReview Published on 2020-12-162022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] acute respiratory syndrome anti-CD20 treatment asked cardiovascular diseases Chronic diseases Coronavirus-2 COVID-19 described disease Disease-modifying therapies experience Healthcare system immunosuppressive therapy information invasive mortality rate Multiple multiple sclerosis non-invasive ventilation outcome pandemic participant Patient patients physician positive Protective reducing required review risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic sclerosis substantial risk the cytokine storm the disease therapy with COVID-19 [DOI] 10.3390/jcm9124067 PMC 바로가기 [Article Type] Review
COVID-19 Impact on Lymphoma Patients’ Clinical Outcomes – an Observational Cohort StudyConference abstract Published on 2020-11-042022-10-05 Journal: Blood [Category] 유전자 메커니즘, [키워드] 30-Day mortality abnormality absolute neutrophil count active cancer advanced age age anti-CD20 therapy anti-CD20 treatment antibody Antibody test baseline board Cancer CD20 clinical clinical information Clinical outcome CLL cohort study conducted continuous variable contributing to cough COVID-19 COVID-19 diagnosis COVID-19 infection COVID-19 PCR test COVID-19 related mortality CRP current death demographic determine diabete diabetes Diagnosis died distribution DLBCL download Electronic health record equity ferritin Fever figure funding higher risk hypertension IgG antibody immune Immunity Impact indolent Infection Infinity IQR Kaplan-Meier method Kite Lymphocyte count lymphoma male Mann-Whitney marker mechanical ventilation median median age median time multicenter naïve number of comorbidities Observational cohort study Other outcome parameter Patient patients patients required hospitalization patients treated patients with SARS-CoV-2 Pearson performance status presenting symptom receive Regional repeated reported required retrospective risk Sample size SARS-CoV2 Seattle seronegative seropositive Shortness of breath shown significantly lower significantly more speaker subtype survival T cell tested the median therapy treated treated patient Treatment university variable variables viral shedding was obtained while with COVID-19 [DOI] 10.1182/blood-2020-141871 [Article Type] Conference abstract